Joseph Cambio, MD
Urology · West Warwick, RINPI 1346245305
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,535 of the $4,025 with a category attached, or 87.8%. It is spread thinly across 32 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations.
Across 135 payments — averaging $29.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$800
- Axonics, Inc.$686
- Astellas Pharma US Inc$355
- Bayer$221
- Sumitomo Pharma America, Inc.$206
- Pfizer$188
- plus $2K from 26 others
What the payments were for
- Travel & lodging$43611%
- Food & beverage$3,53588%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 12 | $800 |
| Axonics, Inc. | 8 | $686 |
| Astellas Pharma US Inc | 21 | $355 |
| Bayer | 9 | $221 |
| Sumitomo Pharma America, Inc. | 10 | $206 |
| Pfizer | 10 | $188 |
| Dendreon Pharmaceuticals LLC | 7 | $167 |
| AbbVie(2 entities) | 11 | $150 |
| Blue Earth Diagnostics | 2 | $145 |
| Neotract Inc. | 3 | $107 |
| Antares Pharma, Inc. | 5 | $107 |
| Endo USA, Inc. | 3 | $78 |
| Urovant Sciences Inc | 3 | $71 |
| Johnson & Johnson | 2 | $69 |
| Coloplast | 3 | $69 |
| AstraZeneca | 3 | $66 |
| Innovation Technologies Inc | 1 | $62 |
| Olympus America Inc. | 3 | $55 |
| Profound Medical Corp. | 2 | $51 |
| Endo Pharmaceuticals Inc. | 2 | $47 |
| Histosonics, Inc. | 1 | $47 |
| Medtronic | 2 | $38 |
| Caris MPI, Inc. | 1 | $32 |
| Myovant Sciences Inc. | 2 | $31 |
| Laborie Medical Technologies Corp. | 2 | $29 |
| Procept Biorobotics Corporation | 1 | $28 |
| Novo Nordisk | 1 | $27 |
| Agiliti Surgical, Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Palette Life Sciences, Inc. | 1 | $19 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Valencia Technologies Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$565
- Axonics$340
- Axonics r-SNM System$122
- Axumin$117
- Bulkamid$113
How this compares
$4,025 in reported general payments places this provider in the 65th percentile of 55 urology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 65 | $34,847 |
| GemtesaVibegron | 51 | $33,902 |
| Tamsulosin Hcl | 606 | $8,597 |
| Finasteride | 482 | $7,362 |
| Potassium Citrate ErPotassium Citrate | 41 | $2,428 |
| Oxybutynin Chloride ErOxybutynin Chloride | 74 | $2,210 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 47 | $1,086 |
| Bicalutamide | 27 | $789 |
| Methenamine Hippurate | 22 | $707 |
| Dutasteride | 29 | $589 |
| Doxazosin Mesylate | 14 | $577 |
| Solifenacin Succinate | 21 | $499 |
| Oxybutynin Chloride | 31 | $386 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $314 |
| Cephalexin | 39 | $305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $355 | $34,84765 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $206 | $33,90251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 55 urology providers in Rhode Island.
Other urology in West Warwick
- Mark LeoWest Warwick$13K
- Joseph CambioWest Warwick$11K
- Angelo CambioWest Warwick$9K
- Alexander LubinWest Warwick$5K
- Atip ChatsudthipongWest Warwick$855
- Vincent CatallozziWest Warwick$666
- Dicken KoProvidence$158K
- Gyan PareekProvidence$83K
- Joseph RenzulliProvidence$81K
- Simone ThavaseelanProvidence$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.